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ABSTRACT
Background
Aurora kinases play an essential role in the orchestration of chromosome separation and cytoki-
nesis during mitosis. Small-molecule inhibition of the aurora kinases has been shown to result in
inhibition of cell division, phosphorylation of histone H3 and the induction of apoptosis in a num-
ber of cell systems. These characteristics have led aurora kinase inhibitors to be considered as
potential therapeutic agents.
Design and Methods
Aurora kinase gene expression profiles were assessed in 101 samples from patients with acute
myeloid leukemia. Subsequently, aurora kinase inhibitors were investigated for their in vitro effects
on cell viability, histone H3 phosphorylation, cell cycle and morphology in acute myeloid
leukemia cell lines and primary acute myeloid leukemia samples.
Results
The aurora kinase inhibitors AZD1152-HQPA and ZM447439 induced growth arrest and the accu-
mulation of hyperploid cells in acute myeloid leukemia cell lines and primary acute myeloid
leukemia cultures. Furthermore, both agents inhibited histone H3 phosphorylation and this pre-
ceded perturbations in cell cycle and the induction of apoptosis. Single cell cloning assays were
performed on diploid and polyploid cells to investigate their colony-forming capacities. Although
the polyploid cells showed a reduced capacity for colony formation when compared with their
diploid counterparts, they were consistently able to form colonies.
Conclusions
AZD1152-HQPA- and ZM447439 are effective apoptosis-inducing agents in acute myeloid
leukemia cell lines and primary acute myeloid leukemia cultures. However, their propensity to
induce polyploidy does not inevitably result in apoptosis.
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Introduction
The aurora kinase family of serine/threonine proteins
regulates many processes during cell division.1-4 Accurate
mitotic chromosome separation is essential for maintaining
the correct ploidy of cells. Three forms of aurora kinase
exist, aurora kinases A, B and C; all have a highly conserved
kinase domain but differ in their N-terminal regions, which
vary in length and show little or no similarity.5 Proliferating
cells express aurora kinases A and B and these are overex-
pressed in tumor cells; furthermore, gene amplification of
aurora kinase A has been reported in breast, ovarian, colon,
prostate, neuroblastoma and cervical cancer cells.6-10
Overexpression resulted in centrosome amplification, chro-
mosomal instability and transformation in mammalian
cells.8,11 The aurora kinase A family functions in centrosome
separation and localizes at the centrosomes, spindle poles
and spindle microtubules, in prophase to telophase.4-6
Aurora kinase A protein levels and kinase activity are both
increased in the late G2-M phase.1 In diploid cells, aurora
kinase B localizes to the centromere in prophase and
metaphase, then transfers to the cortex and spindle mid-
zone in anaphase. Aurora kinase B is localized to the com-
pacted mid-zone in telophase.12 Histone H3 phosphoryla-
tion is important for chromosome condensation and is con-
trolled by aurora kinases A and/or B.5,6,13 Inhibition of his-
tone H3 phosphorylation has been reported to prevent ini-
tiation of chromosome condensation and entry into mito-
sis, implying that phosphorylation of histone H3 is essen-
tial for entry into mitosis,14 although other reports have
shown progression of cells through mitosis with normal
kinetics in the absence of histone H3 phosphorylation.15
Ribonucleic acid interference (RNAi) of aurora kinase A
expression in the HeLa cell line impaired entry to mitosis,
although DNA replication was unaffected. RNAi-targeted
cells are delayed in the G2 phase.3 RNAi inhibition of auro-
ra kinase A, B or both in HeLa, Calu6 and U2OS cells
showed that lack of aurora kinase A in these cells resulted
in an increase in mitotic index, elevated cyclin B1 levels and
spindle defects. Prevention of the function of aurora kinas-
es A and B by treatment with dual inhibitors resulted in a
phenotype resembling that caused by the inhibition of
aurora kinase B, with DNA endoreduplication in the
absence of cytokinesis.16 Several novel small-molecule
inhibitors of the aurora kinases have been developed and
have all shown similar effects on cell lines.13 The aurora
kinase inhibitors ZM447439, AZD1152, VX-680 and hes-
peradin all resulted in inhibition of histone H3 phosphory-
lation and cell division. The effects of prolonged exposure
were dependent on the cell lines, with some exhibiting
massive polyploidy during progression through additional
cell cycles without division, while others showed arrest in
a pseudo G1 state or apoptosis.13,15,17,18 The aurora kinases
have an ATP-binding site with an adjacent cleft, which is
not present in other kinases. ZM447439 binds both the
ATP-binding site and the adjacent cleft thus giving this
inhibitor its specificity for aurora kinases. The sequence
homology between aurora kinases A, B and C has suggest-
ed that they are inhibited by ZM447439 through  the same
mechanism.15,19 A panel of cell lines (A549, DLD-1, U2OS
and HeLa) that had been treated with ZM447439 accumu-
lated with 4N DNA content and undetectable histone H3
phosphorylation.15 Treatment of 3T3 cells, Xenopus eggs or
egg extracts with ZM447439 resulted in inhibition of his-
tone H3 phosphorylation and polyploidy.20,21 Previous stud-
ies have reported an IC50 value for ZM447439 of 1000 nM
for aurora kinase A and 50 nM for aurora kinase B.22
AZD1152 was shown to be effective on SW620 tumors in
nude mice after a single dose resulted in significant and
durable inhibition of tumor growth; as a result this com-
pound has been selected for clinical evaluation.23 AZD1152
is 1000-fold more selective for aurora kinase B than for
aurora kinase A with Ki values of 1300 nM and 0.36 nM for
aurora kinase  A and B, respectively.24
The aim of this study was to assess the level of expres-
sion of the aurora kinases in primary AML blasts and to
determine the effects of two aurora kinase inhibitors,
AZD1152-HQPA and ZM447439, on myeloid cell lines and
primary samples from patients with AML. 
Design and Methods
Cell culture 
Cell lines were maintained in their appropriate medium.
The NB4 and NB4R2 cell lines were maintained in Roswell
Park Memorial Institute (RPMI) medium (Sigma UK Ltd.,
Poole, UK) with 10% fetal bovine serum (FBS; Invitrogen
Ltd, Paisley, UK). The HL60, K562 and U937 cell lines were
maintained in RPMI, 10% FBS, and 1% penicillin/strepto-
mycin (Sigma UK Ltd.). The KG1 cell line was maintained
in Iscove’s modified Dulbecco’s medium (IMDM; Sigma
UK Ltd.), 20% FBS and 1% penicillin/streptomycin. The
cells were kept at concentrations between 2×105 and
1×106/mL. Bone marrow and venous blood samples were
collected in preservative-free heparin or EDTA from newly
diagnosed AML patients entering the United Kingdom
Medical Research Council (UK MRC) AML14 and AML15
trials at hospitals throughout the UK. Primary cells extract-
ed from bone marrow or peripheral blood of AML patients
enriched by density gradient centrifugation with
Histopaque (Sigma UK Ltd.) were maintained in RPMI
medium with 10% FBS and 1% penicillin/streptomycin.
All cultures were kept at 37°C, 5% CO2. Human samples
involved in this study were donated following written
informed consent using documentation approved by the
Medical Research Ethics Committee and the institutional
review board of the University Hospital of Cardiff, Wales.
Cell imaging
Cytospin preparations of cell lines treated with the auro-
ra kinase inhibitors at 0.01 µM were prepared, stained
with modified Wright’s stain and viewed by light
microscopy.
Cell viability and cell counting
Cell viability was measured by trypan blue exclusion,
and the expansion of cultures was quantified by manual
cell counting using a hemocytometer on sequential days in
culture following treatment of cell lines with AZD1152-
HQPA and ZM447439 at concentrations of 1.0, 0.1 and
0.01 µM. 
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Annexin V positivity
Annexin V positivity was determined in treated cells
using the Alexis Biochemicals Annexin V-FITC Apoptosis
Detection Kit (Axxora (UK) Ltd., Nottingham, UK) accord-
ing to the manufacturer’s instructions. Briefly, following
treatment for 48 hours with the inhibitors the cells were
washed in phosphate-buffered saline (PBS) and resuspend-
ed in the supplied binding buffer containing calcium chlo-
ride and incubated with annexin V-fluoroscein-isothio-
cyanate (FITC) in the dark for 10 minutes. Untreated sam-
ples were also prepared in this manner. Cells were then
washed with PBS and resuspended in the supplied binding
buffer and 1 µg/mL propidium iodide (Sigma) added. Data
on the annexin V positivity of the cells were collected on a
FACScalibur and analyzed using WinMDI software.
Histone H3 phosphorylation status and cell cycle
analysis
The phosphorylation status of histone H3 was deter-
mined by flow cytometry. Cell lines and primary cells
were treated with 0.1 µM and 0.01 µM concentrations of
both inhibitors for 24 and 48 hours alongside untreated
control cultures of the same cells. After 24 and 48 hours the
cells were harvested by centrifugation, washed in PBS,
resuspended by vortexing in ice-cold 70% ethanol and
stored at –20°C until analysis. Cells were rehydrated with
0.5 mL PBS (Invitrogen Ltd.) with 1% bovine serum albu-
min (PBS/BSA; Sigma) and centrifuged to remove residual
ethanol. Cells were then resuspended in 200 µL PBS/BSA
with 0.25% Triton X100 (Sigma) and incubated on ice for
20 minutes. A washing step with 0.5 mL PBS/BSA was per-
formed and the cells were incubated overnight in 400 µL
PBS/BSA and anti-phospho histone H3 antibody (Upstate
Cell Signaling Solutions, Lake Placid, NY, USA) at 4°C.
Following the overnight incubation, cells were washed
with PBS/BSA and incubated with FITC-goat anti-rabbit
secondary antibody (Jackson ImmunoResearch Labora-
tories, West Grove, PA, USA) in PBS/BSA for 1 hour in the
dark at 4°C. Cells were washed with PBS/BSA and resus-
pended in 50 µL (10 µg/mL) propidium iodide and 10
µg/mL RNase (Sigma). Fluorescence data on the cells were
collected using a FACScalibur (BD UK Ltd., Cowley,
Oxfordshire, UK) and analyzed using WinMDI software.
Cell cycle analysis was performed using Cylchred soft-
ware. This software was used to determine the percentage
of cells in the sub-G1 (<G1), G1, S, G2, and greater than G2
(>G2) regions of the cell cycle. 
Gene expression analysis
Expression levels of aurora kinases A, B and C were val-
idated by quantitative reverse transcriptase polymerase
chain reaction  (RQ-PCR) which was performed on 101
patients’ samples. Primers used for RQ-PCR were: 
AuroraAR 5’ ACTGACCACCCAAAATCTGC 3’ 
AuroraAL 5’ TGGAATATGCACCACTTGGA 3’
AuroraBR 5’ GGCGATAGGTCTCGTTGTGT 3’
AuroraBL 5’GGGAGAGCTGAAGATTGCTG 3’
AuroraCR 5’ACCAGCCAAAATCTTGCAATC 3’
AuroraCL 5’ GAATATGCTCCAAGGGGTGA 3’
Clonogenicity assays in treated cell lines
AML cell lines were treated with the aurora kinase
inhibitors (0.01 µM) for 48 hours before being washed
and re-plated into fresh medium. Polyploid cells were
distinguished on the basis of their forward scatter and
side light scatter characteristics; being larger than diploid
cells in the untreated cell populations derived from the
same cell line. Clumps of cells were discriminated from
genuine polyploidy by using pulse width (time of flight)
through the laser beam. Polyploid cells were sorted such
that one cell was introduced into each well of a 96-well
plate. Untreated cells of each cell line were also sorted in
the same manner to act as a control for any effects of the
cell sorting process. The treated and untreated control
cells placed into the 96-well plates were incubated at
37°C in 5% CO2 for 7 days before an assessment of
colony formation (>50 cells) or clusters (>5 cells, <50
cells) by light microscopy. 
Results
Expression of aurora kinases in primary AML samples
The relative levels of aurora kinases A, B and C were
determined by RQ-PCR on RNA extracted from the
myeloid cell lines and 101 samples from patients with
AML; only 51 samples were analyzed for aurora kinase
C (Table 1). Aurora kinase C was shown to be absent in
all cell lines and patients’ samples tested. Aurora kinase
A and aurora kinase B were expressed in all cell lines,
with the expression in HL60 cells being double that in
KG1 (the cell line with the lowest expression level). A
wide range (>2 log difference) of expression of aurora
kinase A and aurora kinase B was seen in primary AML
samples. Nearly 10% of patients had significant expres-
sion of aurora kinase B (>0.01 relative to the control S14
gene). Aurora kinase A gene expression indicated that
this isoform was more widely expressed in primary
AML samples (~37%) and there were clear correlations
with FAB groups; the majority of samples (92%) from
patients with M3 AML were positive for aurora kinase
A expression, whereas most samples (85%) from
patients with M4 AML were negative for aurora kinase
A expression (Table 1). No correlation with age or sex
was observed. Expression of aurora kinases A and B was
also determined using the Affymetrix gene expression
system in normal donor bone marrow samples and in a
panel of AML cell lines. These data are shown in Online
Supplementary Figure S1. There was good correlation
between the results achieved using RQ-PCR and the
Affymetrix system.
Morphological effect aurora kinase inhibitors on cell
lines
The effect of treating cell lines with 0.01 µM AZD1152-
HQPA and ZM447439 for 48 hours on the morphology of
the cells was observed by light microscopy and digital
images of the cells were recorded (Figure 1A, B, C).
Treatment with both aurora kinase inhibitors resulted in
a visible increase (approximately doubling) in cell size
when compared to untreated cells at 48 hours, with clear
morphological evidence of apoptosis in the majority of
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cells. A more quantitative assessment of the changes in
the untreated and treated cells was obtained using flow
cytometry. AZD1152-HQPA-treated cells showed size
increases in a time-dependent manner assessed by
increase in forward light scatter as an index of increasing
cell size (NB4 cells shown in Figure 1D, E, F). The pres-
ence of the large cells in the cultures was accompanied by
an increased level of cellular debris, indicating that the
cells were undergoing apoptosis. 
Effect on cell cycle 
The effect of the aurora kinase inhibitors on the cell
cycle was determined by flow cytometry (Figure 2) fol-
lowing treatment with AZD1152-HQPA and ZM447439
at 1.0 µM (cell lines only), 0.1 µM and 0.01 µM for 48
hours. The treated cell lines (all data shown in Online
Supplementary Table S1) consistently showed an increase
in the percentage of cells with a DNA content of 4N and
>4N following treatment with AZD1152-HQPA, with
concurrent decreases in the percentage of cells with a
DNA content of 2N. Following treatment with
AZD1152-HQPA there were significant increases in the
>4N region (0.01 µM AZD1152-HQPA;  p=0.007) and in
the 4N region (0.1 µM AZD1152-HQPA;  p=0.012) and
decreases in the percentage of cells in 2N (0.01 µM
AZD1152-HQPA; p=0.043). Figure 2A shows the change
in the DNA content of cell lines treated with AZD1152-
HQPA for 48 hours. Treatment of primary AML cells
with AZD1152-HQPA resulted in less noticeable pertur-
bations of the cell cycle (Figure 2B). Analysis of primary
samples treated with AZD1152-HQPA (Online Suppl-
ementary Table S2) showed significantly fewer cells with
a 2N DNA content (0.01 µM, AZD1152-HQPA; p=0.039)
and increased numbers of cells in S phase (0.01 µM,
AZD1152-HQPA; p=0.033; Figure 2B). 
Treatment with ZM447439 resulted in a reduced per-
centage of cells with 2N content (40.9% to 24.5% (1.0
µM, ZM447439); p<0.0001) and an increased percentage
of cells with >4N DNA (1.7% to 3.7% (0.01 µM,
ZM447439; p=0.026, although 1.0 µM ZM447439 result-
ed in 18.2% of cells having >2N DNA content) (Online
Supplementary Table S1). Analysis of primary samples
(Online Supplementary Table S2) treated with ZM447439
(0.01 µM) also produced a decrease in cells with 2N
DNA content (55.7% to 49.80%, p=0.010) and increased
proportions in S phase (24.8% to 30.7%, p=0.012).
Increases in the 4N and >4N regions of the cell cycle
were observed but were not statistically significant
(Figure 2B). 
Effect of AZD1152-HQPA and ZM447439 on the
proliferative capacity of cell lines 
AZD1152-HQPA, at concentrations as low as 0.01
µM,  produced a significant (p≤0.05) decrease in the
ability of NB4 cells to proliferate by 48 hours (Figure 3).
The other cell lines (HL-60, NB4R2, K562, KG1 and
U937) also showed reduced proliferative capacity fol-
lowing treatment with AZD1152-HQPA. The viability
of the NB4 cells was decreased at 48 hours by treatment
with 0.01 µM AZD1152-HQPA (p≤0.05). The other cell
lines also showed decreases in viability following treat-
ment with AZD1152-HQPA. ZM447439 induced a sig-
nificant decrease in the proliferative capacity at the
higher concentration of 1.0 µM in NB4 cells after 24
hours (Figure 3) and the viability of NB4 cells was
reduced after 48 hours with 1.0 µM ZM447439. Similar
effects were seen on the other cell lines (NB4R2, KG1,
Aurora kinase inhibitors in AML 
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Table 1. Gene expression levels of aurora kinases in AML patients
as determined by quantitative RT-PCR. 
>0.01 
Number relative %
analyzed expression expressed p value
Aurora kinase A 101 37 37
M1 22 10 42
M2 23 7 30
M3 11 10 92 p<0.0001 compared 
to non-M3
M4 26 4 15 p<0.01 compared
to non-M4
M5 6 2 33
Others 13 4 31
Aurora kinase B 101 10 10
Aurora kinase C 51 0 0
Figure 1. Morphological evidence of
the changes in NB4 cells as a result
of treatment with aurora kinase
inhibitors. (A) Untreated NB4 cells.
(B) NB4 cells treated with AZD1152-
HQPA (0.01 µM) for 48 hours and (C)
NB4 cells treated with ZM447439
(0.01 µM) for 48 hours. All images
are at 40X magnification. Sizes of
untreated NB4 cells (red) and cells
treated with 0.01 µM AZD1152-
HQPA (black) for (D) 24 hours, (E) 48
hours and (F) 72 hours measured by
forward light scatter using flow
cytometry. The same pattern of
increasing cell size with treatment
was only observed when NB4 cells
were treated with ZM447439 at 1.0
µM, while lower concentrations had
no effect on cell size. Data are repre-
sentative of three repetitions of this
experiment. 
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K562, HL60 and U937), which also showed reduced
proliferation following treatment with ZM447439.
Annexin V expression was measured in NB4 cells fol-
lowing treatment with the inhibitors for 48 hours. The
results presented in Online Supplementary Figure S2 show
that apoptosis was induced in the cells in a concentra-
tion-dependent manner.
Effect of AZD1152-HQPA and ZM447439 on
phosphorylation of histone H3 
Histone H3 phosphorylation on serine 10 was meas-
ured by flow cytometry following treatment of cell lines
and primary AML samples with the aurora kinase
inhibitors for 24 and 48 hours at a range of concentra-
tions. Figure 4A illustrates the gating strategy used in
order to identify cells with phosphorylated histone H3.
The level of phosphorylated histone H3 detectable in
untreated cell lines was low (approximately 2.1±1.89%
of cells showed phosphorylation) and even lower in the
primary samples (1%). Treatment of cell lines with
AZD1152-HQPA for 24 or 48 hours produced significant
decreases in the level of phosphorylated histone H3
present in the cells (Figure 4B). After 24 hours of treat-
ment with 0.1 µM AZD1152-HQPA, histone H3 was
reduced to 63% of the level in untreated controls
(p=0.029) with a further reduction observed after 48
hours of treatment to 39% of untreated levels (p=0.044).
Primary AML cells treated with 0.1 µM AZD1152-
HQPA (Figure 4B) showed a decrease in histone H3
phosphorylation after 24 hours to 78% of the control
level (p<0.0001) and after 48 hours 0.01 µM AZD1152-
HQPA resulted in reduction to 63% of the control level
(p=0.043). In cell lines, the effect of 48 hours of treat-
ment with ZM447439 was a significant decrease in
phosphorylation to 60% of the control level (p=0.006).
In primary samples from AML patients, 0.1 µM
ZM447439 inhibited phosphorylation of histone H3 to
58% of the control level by 48 hours (p<0.0005).
Correlation between expression of aurora kinases and
response to inhibitors
To determine whether the primary cells expressing
aurora kinases A and B had an increased response to the
inhibitors, samples expressing and not expressing aurora
kinases were assessed for their responses to treatment
with the inhibitors. A response was defined as an increase
in annexin V positivity, a decrease in histone H3 phos-
phorylation or an increase in the percentage of cells with
a >4N DNA content after 48 hours of treatment. An
increase in annexin V expressing cells was seen in 57% of
aurora kinases A-expressing cells, 67% of aurora kinases
B-expressing cells and in 58% of cells that did not express
either aurora kinases A or B. Histone H3 phosphorylation
was seen in 50% of cells expressing aurora kinase A or B
and in 58% of the cells that did not express either aurora
kinase. An increase in the percentage of cells with >4N
DNA was seen in 50% of the aurora kinase A-expressing
samples, in 67% of the aurora kinase B-expressing sam-
ples and in 50% of the samples that did not express either
aurora kinase. From these results it is clear that there is no
correlation between aurora kinase expression and
response to aurora kinase inhibition.
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Figure 2. The effect on cell cycle resulting from treatment with vary-
ing concentrations of aurora kinase inhibitors for 48 hours was
assessed using cylchred software. (A) The distribution of six myeloid
cell lines assayed in triplicate and (B) primary cells from 30 AML
patients treated with the indicated concentrations of AZD1152-
HQPA and ZM447439 are shown in the histograms. *Denotes a
change in cell cycle distribution that is significantly different from
that in the untreated population (p<0.05) measured using a paired
t test. Error bars indicate ± one standard deviation.
Figure 3. NB4 cells were treated with concentrations of AZD1152-
HQPA and ZM447439 between 1.0 µM and 0.01 µM for 72 hours.
The growth and viability of the cells were recorded at 24 hour inter-
vals to assess the effect of the aurora kinase inhibitors on the cells.
Experiments were repeated in triplicate. All concentrations of
AZD1152-HQPA used proved to be effective at reducing the growth
and viability of the NB4 cells while only the highest concentration
of ZM447439 resulted in the same effect on the NB4 cells.
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Clonogenic potential of aurora kinase-induced
polyploid cells 
Polyploid cells induced by a single 48-hour exposure to
aurora kinase inhibitors (0.01 µM) were isolated by high-
speed cell sorting directly into 96-well plates containing
culture media (one cell per well). Cell lines treated with
AZD1152-HQPA or ZM447439 showed reduced colony-
forming ability compared with that of the untreated con-
trol cells. The average colony growth across all the cell
lines was reduced from 391 colonies to 134 colonies
when the cells were treated with AZD1152-HQPA
(p=0.003) and to 154 colonies when they were treated
with ZM447439 (p=0.022). The numbers of colonies
grown following treatment and re-plating in fresh medi-
um are shown in Figure 5. 
Discussion
Depending on their age, 50-70% of adults with AML
achieve a complete remission but only 20-30% of these
experience long-term disease-free survival with conven-
tional chemotherapy.25 Improvements in clinical out-
comes, particularly in patients over 55 years old, have
been modest,25 as these patients do not tend to tolerate
intensive chemotherapeutic regimens and frequently
have poor prognosis cytogenetics.27 Overall survival rates
in older patients are less than 10%.25,26 This inability to
successfully treat older patients with AML underlies the
continuing need to develop new treatments for AML. 
This study is the first report of aurora kinase expres-
sion levels in patients with AML. We found that aurora
kinase A was expressed in 37% of primary AML sam-
ples, while aurora kinase B was only expressed in 10% of
such samples. The low mitotic rate of AML cells in in vitro
culture may be one reason why only some of the popu-
lation were found to express these kinases. Interestingly,
there appeared to be a correlation between aurora kinase
expression and FAB group, with the M3 subtype pre-
dominantly exhibiting aurora kinase A expression, while
the M4 subtype usually had very low expression of both
aurora kinase A and aurora kinase B. The expression of
the aurora kinases in a range of cancers (breast, ovarian,
colon, prostate, neuroblastoma and cervical cancer cells)6-
10 in which expression was correlated with tumor pro-
gression suggested that aurora kinases may be a potential
target for treatment. However, given the levels of expres-
sion in primary AML cells, probably only a sub-group of
patients might be responsive to aurora kinase therapy.
Aurora kinase inhibitors in AML 
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Figure 4. The effect of treatment with AZD1152-HQPA and
ZM447439 on phosphorylation of histone H3 in NB4 cells. (A) Flow
cytometry was used to determine the percentage of cells with phos-
phorylated histone H3. Doublets were removed from the analysis
using the R1 gate shown in the first plot. The remaining plots show
propidium iodide staining, used to demonstrate the DNA content of
the cells against the level of phosphorylated histone H3 for each
cell measured. At 48 hours, the untreated population had 2.45%
phosphorylated histone H3 (center) and AZD1152-HQPA -treated
cells (0.01 µM) 2.08% (right) shown in the R2 region on these plots.
(B) The effect of different concentrations of AZD1152-HQPA and
ZM447439 over 48 hours on a range of six cell lines and primary
cells from 30 AML patients was determined by flow cytometry. A
significant difference (p<0.05) in phosphorylation state compared
to that of the untreated control population is indicated by * and was
determined using paired t tests.  
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Figure 5. The effect of plating six myeloid cell lines (HL-60, U937,
NB4, NB4R2, KG1 and K562) treated with aurora kinase inhibitors
AZD1152-HQPA and ZM447439 (0.01 µM) for 48 hours into fresh
medium was assessed by counting the number of colonies of cells
that had grown after 1 week from cells plated into culture dishes as
single cells per well. The experiments were repeated in triplicate
and statistical significance was determined using a paired t test:
*p=0.003 and *p=0.022 for AZD1152-HQPA and ZM447439 com-
pared to untreated, respectively. 
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Although no correlation was seen between expression of
the aurora kinases and response to their inhibition, there
are various possible explanations for this. Our favored
hypothesis is that a critical level of aurora kinase expres-
sion is required to maintain cell viability, meaning that
cells with lower aurora kinase expression may be more
susceptible to aurora kinase inhibition; this hypothesis
does, however, need to be tested experimentally.
Proliferating cells express aurora kinase A and B and auro-
ra kinase A is required for the commitment of human cells
to mitosis.3 Most previous studies3,15-17,28-30 were conducted
on solid tumors and not on circulating blast cells. The
effects of inhibiting the aurora kinases in different types of
cancer suggest that aurora kinase inhibitors trigger apop-
tosis in a proportion of cells and lead to arrest of tumors in
model systems.18 In our studies, both AZD1152-HQPA
and ZM447439 resulted in a decreased proliferative capac-
ity and viability of AML cell lines. This agrees with the
findings of previous studies in which ZM447439 inhibited
proliferation completely and resulted in endoreduplication
in human cell lines.15 Another aurora kinase inhibitor,
VX680, also inhibited proliferation and leukemic cells
were found to be particularly sensitive to this inhibitor.17
Treatment of the cell lines and primary AML material
with the inhibitors AZD1152-HQPA and ZM447439
resulted in the disruption of the cell cycle with accumula-
tion of cells with 4N and >4N DNA content, alongside a
decrease in the proportion of cells with <4N DNA con-
tent. In agreement with the data described here,
ZM447439 has previously been reported to result in accu-
mulation of cells with 4N DNA content in a variety of
human cell lines (A549, MCF-7, DLD-1, HeLa and
U2OS).15 There was also an accumulation of polyploid
cells as a result of treatment with VX-680.5,17
Histone H3 phosphorylation is controlled by the auro-
ra kinases and is important for chromosome condensa-
tion.5,6,13 When histone H3 phosphorylation is inhibited,
chromosome condensation is prevented and entry to
mitosis blocked. Histone H3 phosphorylation was meas-
ured as a means of determining whether the aurora
kinase inhibitors AZD1152-HQPA and ZM447439 had an
effect on the cells. However, the level of histone H3 phos-
phorylation seen in the primary AML cells was low
(~2%) even in the absence of inhibitors. In our study,
phosphorylation of histone H3 was reduced in cell lines
after treatment with AZD1152-HQPA and ZM447439.
This confirms previous reports that ZM447439 treatment
of human cell lines and Xenopus eggs resulted in loss of
phosphorylation of histone H3.15,21 Histone H3 phospho-
rylation was also inhibited in the human cell line MCF-7
and rat cell line PtK2 after treatment with alternative auro-
ra kinase inhibitors, VX-680 and hesperadin, respective-
ly.17,28 These results indicate that the aurora kinases are
indeed inhibited by the aurora kinase inhibitor com-
pounds as histone H3 phosphorylation is a direct down-
stream target of aurora kinase B. Our results extend these
findings, showing that the aurora kinases were inhibited
in both cell lines and primary AML samples.
We have shown that cell lines treated with the
inhibitors for 48 hours, assessed by size and granularity
to be part of the hyperploid population, showed a
reduced capacity to undergo clonal growth when re-plat-
ed as single cells in fresh medium, indicating that recov-
ery from hyperploidy was impaired. This suggests that
the majority of hyperploid cells produced as a result of
treatment with AZD1152-HQPA or ZM447439 are not
capable of recovering once they have reached a certain
stage or DNA content and that they cannot continue to
proliferate. This result is in agreement with previous find-
ings that treatment with ZM447439 for 24 hours fol-
lowed by re-plating in fresh medium without ZM447439
resulted in a dramatic reduction of the number of colonies
formed.22 Another report found that continuous treatment
with VX-680, which inhibits FLT3 as well as the aurora
kinases, completely ablated the colony-forming ability of
primary cells from AML patients with FLT3 mutations,
although this probably reflects the effect of the agent on
proliferation rather than the ability of cells to recover
from exposure to the treatment agent once it has been
removed.17
Other studies have also shown that the effect of
inhibiting the action of aurora kinases is reversible. The
phosphorylation of histone H3 was restored within 30
minutes after removal of hesperadin from PtK2 cells.28
When SU6668, which inhibits aurora kinase A amongst
other kinases, was washed out of HeLa cells, the cells
were able to re-enter the G1 phase. Phosphorylation of
histone H3 on serine 10, thought to be a measure for
aurora kinase activity, was also completely abolished by
the action of SU6668 but recommenced within 30 min-
utes of removal of this inhibitor.30 These findings suggest
that targeting aurora kinases may prove challenging in the
setting of clinical hematology as the inhibitors may have
to be given at frequent intervals or even continuously to
maintain their effect. The aurora kinase inhibitor
AZD1152-HQPA may have potential to treat specific
sub-groups of leukemic cells with overexpression of auro-
ra kinase A. In particular, the M3 sub-type of AML may
be a specific niche for the action of these inhibitors.
However, this study suggests that further investigation of
these drugs is warranted, particularly AZD1152-HQPA,
which appears more effective than ZM447439 in AML
cell lines and primary cells.
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